Science ❯ Biotechnology ❯ Drug Development

Regulatory Affairs

FDA Approvals FDA Approval

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

The review moves RP1 plus nivolumab into formal evaluation after a June rejection.

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug